NASDAQ: NRBONeurobo Pharmaceuticals Inc Stock
$1.57+0.14 (+9.79%)
Updated Dec 2, 2022
NRBO Price
$1.57
Fair Value Price
$31.88
Market Cap
$10.21M
52 Week Low
$1.13
52 Week High
$63.85
P/E
-0.1x
P/B
1.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.27
Operating Cash Flow
-$13M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NRBO Overview
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRBO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRBO ($1.57) is undervalued by 95.08% relative to our estimate of its Fair Value price of $31.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NRBO ($1.57) is significantly undervalued by 95.08% relative to our estimate of its Fair Value price of $31.88 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NRBO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NRBO due diligence checks available for Premium users.
Be the first to know about important NRBO news, forecast changes, insider trades & much more!
NRBO News
Valuation
NRBO fair value
Fair Value of NRBO stock based on Discounted Cash Flow (DCF)
Price
$1.57
Fair Value
$31.88
Undervalued by
95.08%
NRBO ($1.57) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NRBO ($1.57) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NRBO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NRBO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
13.84x
Market
21.89x
NRBO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.72x
Industry
5.06x
NRBO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NRBO's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
NRBO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.6M
Liabilities
$1.6M
Debt to equity
0.27
NRBO's short-term assets ($7.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRBO's short-term assets ($7.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRBO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRBO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$0.0
Financing
-$134.0k
NRBO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRBO vs Biotech Stocks
Neurobo Pharmaceuticals Stock FAQ
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.